Lisa Rojkjaer

CIK: 0001846460

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)6 (75.0%)

Compensation grants

Other (G, F, J, C, D, …)2 (25.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

RIGL

RIGEL PHARMACEUTICALS INC

Officer

Discretionary Trading P&L

Holdings

Transaction History (8 total)

RIGL
RIGEL PHARMACEUTICALS INC
Jun 17, 2026
Award(A)
Employee Stock Option (right to buy)
Direct
9.4K shares-
RIGL
RIGEL PHARMACEUTICALS INC
Jun 17, 2026
Award(A)
Employee Stock Option (right to buy)
Direct
7.4K shares-
RIGL
RIGEL PHARMACEUTICALS INC
Jun 1, 2026
Tax Payment(F)
Direct
850 shares at avg. $29.86$25K
RIGL
RIGEL PHARMACEUTICALS INC
Feb 17, 2026
Award(A)
Direct
18.9K shares-
RIGL
RIGEL PHARMACEUTICALS INC
Feb 10, 2026
Tax Payment(F)
Direct
3.8K shares at avg. $34.62$130K
RIGL
RIGEL PHARMACEUTICALS INC
Sep 15, 2025
Award(A)
Employee Stock Option (right to buy)
Direct
7.4K shares-
RIGL
RIGEL PHARMACEUTICALS INC
Mar 17, 2025
Award(A)
Employee Stock Option (right to buy)
Direct
9.4K shares-
RIGL
RIGEL PHARMACEUTICALS INC
Jan 29, 2025
Award(A)
Direct
19.7K shares-

		Type	Shares	Price		Ownership
Jun 17, 2026	RIGL RIGEL PHARMACEUTICALS INC	Award(A) Employee Stock Option (right to buy)	9,375	-	-	Direct
Jun 17, 2026	RIGL RIGEL PHARMACEUTICALS INC	Award(A) Employee Stock Option (right to buy)	7,394	-	-	Direct
Jun 1, 2026	RIGL RIGEL PHARMACEUTICALS INC	Tax Payment(F)	850	$29.86	$25,381	Direct
Feb 17, 2026	RIGL RIGEL PHARMACEUTICALS INC	Award(A)	18,894	-	$0	Direct
Feb 10, 2026	RIGL RIGEL PHARMACEUTICALS INC	Tax Payment(F)	3,758	$34.62	$130,102	Direct
Sep 15, 2025	RIGL RIGEL PHARMACEUTICALS INC	Award(A) Employee Stock Option (right to buy)	7,394	-	-	Direct
Mar 17, 2025	RIGL RIGEL PHARMACEUTICALS INC	Award(A) Employee Stock Option (right to buy)	9,375	-	-	Direct
Jan 29, 2025	RIGL RIGEL PHARMACEUTICALS INC	Award(A)	19,717	-	$0	Direct

1-8 of 8 transactions

About Rojkjaer Lisa

Rojkjaer Lisa (SEC CIK 0001846460) files insider reports with the SEC as EVP, Chief Medical Officer of RIGEL PHARMACEUTICALS INC (RIGL).

Signal8 holds 7 ownership filings by Rojkjaer Lisa, all Form 4s, filed between Jan 31, 2025 and Jun 22, 2026. Those filings report 8 transactions, from Jan 29, 2025 to Jun 17, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Rojkjaer Lisa's filings is in SOUTH SAN FRANCISCO, CA.

Recent filings by Rojkjaer Lisa

Jun 17, 2026: Grants or awards of RIGL derivative securities (2 lines, Form 4, code A).
Jun 1, 2026: Tax withholding of RIGL shares (Form 4, code F).
Feb 17, 2026: Grant or award of RIGL shares (Form 4, code A).
Feb 10, 2026: Tax withholding of RIGL shares (Form 4, code F).
Sep 15, 2025: Grant or award of RIGL derivative securities (Form 4, code A).

Other insiders filing for RIGEL PHARMACEUTICALS INC (RIGL)

Schorno Dean L, EVP & Chief Financial Officer
Santos David A, EVP, Chief Commercial Officer
RODRIGUEZ RAUL R, CEO, President
Furey Raymond J., EVP, GC, CCO & Corp Sec
HANNAH ALISON L., EVP, Chief Medical Officer
Ali-Jackson Kamil, Director

How to read Form 4 transaction codes